Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

MDMA-Assisted Massed Exposure Therapy for PTSD

A legfontosabb adatok

Ki végzi
Emory University
Hol
Atlanta (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
200 fő, tervezett
Kezdés
2026. júl.
Várható befejezés
2030. jan.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • 3,4-Methylenedioxymethamphetamine (MDMA)
  • Placebo
  • Massed Prolonged Exposure (PE)
A regiszteradat frissítve
2026. május 26.

Ki vehet részt

Életkor
21 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • PTSD diagnosis as assessed by Clinician-Administered Posttraumatic Stress Scale for DSM-5 - Revised (CAPS-5-R)
  • Able to speak and read English (due to standardization of outcome measures)
  • Willing to sign a release for the investigators to communicate with their primary care or mental health providers if indicated
  • Able to swallow pills
  • Agree to have study visits video and/or audio recorded, including Experimental Session, assessments, and non-drug therapy sessions
  • Willing to provide a contact (relative, spouse, close friend, or another support person) who is willing and able to be contacted by the investigators
  • Agree to inform the investigators within 48 hours of any medical conditions and procedures
  • If able to become pregnant, must have a negative pregnancy test before study entry, at study entry, and before the Medicine Session. Must agree to use adequate birth control for a month before the Medicine session and through 10 days after the Medicine Session
  • Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications before the Medicine Session, and not participating in any other interventional clinical trials during the duration of the study, are driven home or to a hotel after the Medicine Session, and commit to medication dosing, therapy, and study procedures

Ki nem vehet részt

  • Have previously participated in a Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored MDMA clinical trial
  • Have a history of any medical condition that could make receiving MDMA dangerous because of increases in blood pressure and heart rate or any medical condition the study physician believes would pose a safety risk or interfere with the effects of the treatment. Any medical disorder judged by the investigator to significantly increase the risk of MDMA administration by any mechanism is exclusionary
  • Require the use of concomitant medications that could impact the effects or safety of MDMA during the Medicine Session
  • Have engaged in ketamine-assisted therapy or used ketamine within 12 weeks of enrollment
  • Have hypersensitivity to any ingredient of the Investigational Medicinal Product (IMP)
  • Upon review of medical or psychiatric history and psychiatric assessment, have any current or past diagnosis that would be considered a risk to participating in the study
  • Requires ongoing psychiatric medication use with certain exceptions. Individuals may decide to taper psychiatric medications under the guidance of their local provider
  • Have any unstable medical condition that would interfere with participation
  • Have uncontrolled hypertension) documented on three separate occasions
  • Have Wolff-Parkinson-White syndrome or any other accessory pathway that has not been successfully eliminated by ablation
  • Have a history of ever having ventricular arrhythmia or any other abnormal heart rhythm that the study physician believes would pose a significant risk of participation
  • Have symptomatic liver disease or significant liver enzyme elevations
  • Have a history of hyponatremia or hyperthermia
  • Have a history of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Are not able to give adequate informed consent
  • Have any current problem which, in the opinion of the investigator or study physician, might interfere with participation
  • Have an abnormal finding on electrocardiogram
  • Weigh less than 48 kilograms (105 lbs.)
  • Are pregnant or nursing

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 21 és 70 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Emory Brain Health CenterAtlanta, Egyesült ÁllamokContact: Jessica Maples-Keller, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to investigate the efficacy of 3,4-methylenedioxy-methamphetamine hydrochloride (MDMA) combined with Massed Prolonged Exposure (PE) therapy for the treatment of posttraumatic stress disorder (PTSD) in adult participants diagnosed with PTSD. This randomized, placebo-controlled trial will enroll 95 participants.

A teljes eredeti leírásKevesebb

The main questions it aims to answer are:

* Does the combination of PE + MDMA lead to greater reduction in PTSD symptom severity from pre-treatment to one-month follow-up compared to PE + placebo? * Does PE + MDMA improve response efficiency and durability of PTSD symptom improvement compared to PE + placebo? * Does MDMA + PE enhance extinction retention and reduce amygdala threat reactivity, and are these changes associated with improved PTSD outcomes?

Participants will:

* Receive 10 sessions of Massed Prolonged Exposure therapy over two weeks * Be administered either 100 mg of MDMA or a placebo at Visit 2 * Undergo blinded independent evaluator assessments using the Clinician-Administered PTSD Scale for DSM-5-R (CAPS-5-R) at the one-month posttreatment follow-up

A vizsgálat 2 csoportja

  • MDMA groupA vizsgált kezelés

    Kezelés: 3,4-Methylenedioxymethamphetamine (MDMA) és Massed Prolonged Exposure (PE)

  • Standard of CarePlacebo, összehasonlításként

    Kezelés: Placebo és Massed Prolonged Exposure (PE)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Kérdések a feltételekről
Forrás: NCT07288151: ki vehet részt
A regiszteradat frissítve
2026. május 26.